{"title":"Nanoliposome of Linolenic acid for Methicillin-resistant Staphylococcus aureus treatment","authors":"Azmee Okriss, Julinthip Puttawong, Mingkwan Yingkajorn, Somyot Chirasatitsin, Soracha D. Thamphiwatana","doi":"10.1109/BMEiCON56653.2022.10012101","DOIUrl":null,"url":null,"abstract":"Methicillin-resistant Staphylococcus aureus (MRSA) presents a major threat to a broad range of healthcare and community associated infections. MRSA bacteria have rapidly developed resistance to multiple drugs throughout the antibiotic history. It is imperative to develop novel antimicrobial strategies to address the currently shrinking therapeutic options against MRSA. Herein, we developed a nanoliposome formulation of natural antimicrobial compound such as linolenic acid and evaluate its potential application for the treatment of MRSA infection as well as its safety. We found that Nano-liposomal linolenic acid (LipoLNA) was successfully synthesized. LipoLNA was able to inhibit MRSA growth and exhibited a good safety profile on normal mammalian cells.","PeriodicalId":177401,"journal":{"name":"2022 14th Biomedical Engineering International Conference (BMEiCON)","volume":"3 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"2022 14th Biomedical Engineering International Conference (BMEiCON)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1109/BMEiCON56653.2022.10012101","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) presents a major threat to a broad range of healthcare and community associated infections. MRSA bacteria have rapidly developed resistance to multiple drugs throughout the antibiotic history. It is imperative to develop novel antimicrobial strategies to address the currently shrinking therapeutic options against MRSA. Herein, we developed a nanoliposome formulation of natural antimicrobial compound such as linolenic acid and evaluate its potential application for the treatment of MRSA infection as well as its safety. We found that Nano-liposomal linolenic acid (LipoLNA) was successfully synthesized. LipoLNA was able to inhibit MRSA growth and exhibited a good safety profile on normal mammalian cells.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
